The National Biotechnology Safety Act would authorize the National Science Foundation to fund research on the safety and regulatory considerations of biotechnology. It creates a program within NSF to study how organisms produced with biotechnology interact with the environment and health systems, and to help regulators develop clear oversight pathways.
The bill also commissions a National Academies study in two phases to evaluate the safety and benefits of biotechnology and to produce implementation guidance for federal action.
At a Glance
What It Does
The bill establishes an NSF program inside its Directorate for Technology, Innovation, and Partnerships to fund research on the introduction of biotechnology-produced organisms into the environment, using grants, cooperative agreements, and consortia. It also directs regulatory coordination with major agencies and sets research priorities.
Who It Affects
Recipients include colleges and universities, federally funded research and development centers, nonprofit research institutions, industry, and consortia. Federal agencies like the FDA, USDA, and EPA will interact with NSF to shape oversight.
Why It Matters
It creates a structured risk-assessment framework and a clearer regulatory pathway for biotechnology products, aiming to align innovation with safety and environmental health considerations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill assigns NSF a formal program to sponsor biotechnology risk research. It authorizes funding for work that probes environmental and health risks posed by organisms modified with biotechnology and seeks to identify practical regulatory pathways for products arising from these technologies.
Eligible recipients span highereducation institutions, national labs, nonprofit researchers, industry players, and multi-organization consortia. The Director of NSF would select projects based on factors such as potential for commercialization, the current state of knowledge, and the project’s alignment with stated priorities, including the mitigation of unintended effects and the development of monitoring methods for biotechnology products.
A core set of research priorities focuses on identifying unintended genetic changes, environmental and health risks, and effective management practices for field trials, production, and end-use. It also emphasizes tracking gene drives, gene transfer between organisms, and comparing biotechnology-modified organisms to conventional counterparts or other human activities.
The bill directs consideration of how biotechnology may converge with artificial intelligence and other emerging technologies, and allows metrics to be set to gauge progress and eligibility for continued funding.In addition to NSF funding, the act requires coordination with the Department of Agriculture, FDA, EPA, and other agencies to ensure research aligns with regulatory needs and oversight. The act earmarks $50 million per year for FY 2026–2030 and permits the Director to prioritize this program and leverage other available funds.
It also requires a parallel National Academies study to assess safety and benefits in two phases, with public-facing reports and a plan to close any remaining research gaps via a federal implementation strategy.
The Five Things You Need to Know
The bill authorizes an NSF risk-research program focused on biotechnology safety.
Funding is set at $50 million per fiscal year from 2026 through 2030.
Eligible recipients include universities, FFRDCs, nonprofits, industry, and consortia.
Priority research areas cover unintended effects, risk management, monitoring, gene drives, and AI convergence.
A National Academies two-phase study will report findings and an implementation plan to Congress.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings and purpose
This section states Congress’s intent that biotechnology safety research informs regulatory decision-making and stakeholder confidence. It frames biotechnology’s broad use and the need for a systematic, risk-based approach to assessing environmental and health implications, setting the stage for the NSF program and the Academies study that follow.
Biotechnology risk assessment research program
The Director of NSF must establish a program within the Directorate for Technology, Innovation, and Partnerships to fund research on the environmental introduction and impacts of biotechnology-produced organisms. Funding mechanisms include grants, cooperative agreements, and temporary consortia. Recipients span higher education, federally funded R&D centers, nonprofit institutions, industry, and consortia. NSF must use explicit selection criteria, prioritizing risk assessment, potential for mitigating risks, and alignment with national research priorities; it may consider metrics to guide ongoing funding and determine eligibility for continued support. Regulatory coordination with USDA, FDA, EPA, and other agencies ensures oversight and practical applicability.
National Academies study and reports
NSF, in coordination with relevant federal agencies, must enter into an agreement with the National Academies to conduct a two-phase study on biotechnology safety and benefits. Phase one, due within one year of the agreement, will compare biotech tools to conventional methods, propose risk-proportionate frameworks, and identify further research needs. Phase two, due within two years, will assess safety and benefits alongside conventional products and other activities, and recommend processes to streamline or adjust oversight for low-risk biotechnology products. The Academies must submit report findings to Congress and make them publicly available; an implementation plan to close research gaps must follow within 180 days after all reports are submitted.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Universities and research institutes receive funding for biotechnology risk research and collaboration opportunities.
- Federally funded research centers and nonprofit laboratories gain grant-based opportunities and partnerships.
- Private sector biotech firms benefit from clearer regulatory pathways and data to guide product development.
- Regulators and policymakers gain independent assessments to inform oversight and timely decision-making.
Who Bears the Cost
- Federal government funds the NSF program and Academy studies, funded through annual appropriations.
- Awarded institutions incur administrative costs and reporting obligations associated with managing grants.
- Regulatory agencies incur coordination and oversee additional research activities and interagency communication.
Key Issues
The Core Tension
Balancing rigorous risk assessment and regulatory clarity with the need to avoid stifling biotechnology innovation and speed-to-market, while ensuring coordination across multiple agencies and independent oversight.
The bill advances safety science for biotechnology by funding targeted risk research and requiring an independent, two-phase evaluation by the National Academies. However, the approach relies on robust interagency coordination and timely execution by multiple actors, raising questions about the potential for overlapping or duplicative oversight across agencies and the risk of regulatory bottlenecks if metrics and implementation plans are not well calibrated.
The funding is finite and tied to annual appropriations, which could affect program stability and long-term ambition if budgets shift. Additionally, the scope of what constitutes “safety and benefits” may evolve as technology advances, creating ongoing negotiation between precaution and innovation.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.